Highlights

Roth Capital Starts Coverage on AEterna Zentaris (AEZS)

 Source: ABMN Staff   |   Publish date: Thu, 20 Sep 2012, 08:04 AM   |    >> Read article in News website

Research analysts at Roth Capital began coverage on shares of AEterna Zentaris (NASDAQ: AEZS) in a report released on Thursday. The firm set a “buy” rating on the stock.

AEterna Zentaris opened at 0.6801 on Thursday. AEterna Zentaris has a 1-year low of $0.38 and a 1-year high of $2.17. The company’s market cap is $76.4 million.

A number of other firms have also recently commented on AEZS. Analysts at Oppenheimer reiterated a “perform” rating on shares of AEterna Zentaris in a research note to investors on Thursday, August 16th. Analysts at RBC Capital cut their price target on shares of AEterna Zentaris from $0.70 to $0.55 in a research note to investors on Thursday, August 16th. They now have a “sector perform” rating on the stock.

Aeterna Zentaris Inc. (Aeterna Zentaris) is a drug development company specialized in oncology and endocrine therapy.

Share this

  Be the first to like this.
 


 

3161  3836  796  557 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 ZAIS 2.92+0.82 
 BAC 23.12+0.18 
 MU 28.43+1.96 
 XLF 23.54+0.02 
 SPY 233.86-0.42 
 VXX 16.77+0.28 
 EEM 39.81+0.11 
 HTGM 9.65+7.51 
 AFH 13.45+0.10 
 FXN 14.38-0.11 
Partners & Brokers